Investors were not irritated by President Donald Trump’s threat of veto against the corona stimulus package passed by Congress. The most recently published economic data also had hardly any discernible influence on the stock market barometer.
The market-wide S&P 500 was also up by 0.58 percent to 3708.79 points in the middle of the week. The technology-heavy Nasdaq 100 showed little change with plus 0.05 percent to 12,723.91 points.
Sales are now also decreasing in New York before Christmas. Trading will take place again on Thursday, but the stock exchanges will close three hours earlier than usual.
On the company side, the focus was on the medical industry. At Biontech, the enthusiasm of investors about the delivery of an additional 100 million doses of their corona vaccine to the US government was limited: The air is out of the New York-listed shares of the Mainz company, they recently lost another 0.8 Percent one. For the titles of the Biontech vaccine partner Pfizer, things went in the other direction this time after the recent weak phase: They won 2.2 percent.
The shares of Merck & Co gained 1.2 percent. The pharmaceutical company will receive up to around 365 million US dollars from the US government for the possible delivery of 60,000 to 100,000 doses of a drug against the lung disease Covid-19 to the US government. However, the drug is not yet approved.
The shares of Supernus Pharmaceuticals jumped more than 17 percent. In an advanced clinical study with its drug candidate for ADHD in adults, the company achieved the so-called primary endpoint, i.e. the main objective of the study.
There was another setback for the shareholders of the electric truck manufacturer Nikola with a minus of almost ten percent. The reason is an order cancellation by the US disposal company Republic Services for 2500 battery-operated garbage trucks.
Financials took the lead in the Dow. Goldman Sachs, JPMorgan and American Express gained between three and four percent./ajx/he
(AWP)
–
